These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 31739672)

  • 1. Baseline characteristics, diagnostic efficacy, and peri-examinational safety of IV gadoteric acid MRI in 148,489 patients.
    Braun J; Busse R; Darmon-Kern E; Heine O; Auer J; Meyl T; Maurer M; Hamm B; de Bucourt M
    Acta Radiol; 2020 Jul; 61(7):910-920. PubMed ID: 31739672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic efficacy and safety of gadoteric acid MR mammography in 1537 patients.
    Seithe T; Braun J; Wolf M; Vahldiek J; Wolny D; Auer J; Pociej J; Heine O; Hamm B; de Bucourt M
    Eur J Radiol; 2016 Dec; 85(12):2281-2287. PubMed ID: 27842678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability and diagnostic value of gadoteric acid in the general population and in patients with risk factors: results in more than 84,000 patients.
    Maurer M; Heine O; Wolf M; Durmus T; Wagner M; Hamm B
    Eur J Radiol; 2012 May; 81(5):885-90. PubMed ID: 21555197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study.
    Soyer P; Dohan A; Patkar D; Gottschalk A
    J Magn Reson Imaging; 2017 Apr; 45(4):988-997. PubMed ID: 27726239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of gadoteric acid in pediatric magnetic resonance imaging: overview of clinical trials and post-marketing studies.
    Balassy C; Roberts D; Miller SF
    Pediatr Radiol; 2015 Nov; 45(12):1831-41. PubMed ID: 26045036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA).
    Herborn CU; Honold E; Wolf M; Kemper J; Kinner S; Adam G; Barkhausen J
    Invest Radiol; 2007 Jan; 42(1):58-62. PubMed ID: 17213750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse Reactions to Gadoterate Meglumine: Review of Over 25 Years of Clinical Use and More Than 50 Million Doses.
    de Kerviler E; Maravilla K; Meder JF; Naggara O; Dubourdieu C; Jullien V; Desché P
    Invest Radiol; 2016 Sep; 51(9):544-51. PubMed ID: 27504794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of gadoterate meglumine (Gd-DOTA) as a contrast agent for magnetic resonance imaging: results of a post-marketing surveillance study in Japan.
    Ishiguchi T; Takahashi S
    Drugs R D; 2010; 10(3):133-45. PubMed ID: 20945944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of use, effectiveness and safety of gadolinium contrast agents: a European prospective cross-sectional multicentre observational study.
    Jakobsen JÅ; Quattrocchi CC; Müller FHH; Outteryck O; Alcázar A; Reith W; Fraga P; Panebianco V; Sampedro A; Pietura R
    BMC Med Imaging; 2021 Apr; 21(1):74. PubMed ID: 33879075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Multicenter analysis of tolerance and clinical safety of the extracellular MR contrast agent gadobenate dimeglumine (MultiHance)].
    Herborn CU; Jäger-Booth I; Lodemann KP; Spinazzi A; Goyen M
    Rofo; 2009 Jul; 181(7):652-7. PubMed ID: 19291607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraventricular Gadoteric Acid Intoxication: First Report.
    Turk O; Ozdemir NG; Atci IB; Saygi T; Yilmaz H; Antar V
    World Neurosurg; 2018 Mar; 111():264-268. PubMed ID: 29292188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of gadoterate meglumine in children younger than 2 years of age.
    Farmakis SG; Hardy AK; Mahmoud SY; Wilson-Flewelling SA; Tao TY
    Pediatr Radiol; 2020 May; 50(6):855-862. PubMed ID: 32055917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem®) examinations, including 3,209 performed on renally insufficient individuals.
    Young LK; Matthew SZ; Houston JG
    Eur Radiol; 2019 Apr; 29(4):1922-1930. PubMed ID: 30276674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical safety of gadopentetate dimeglumine.
    Nelson KL; Gifford LM; Lauber-Huber C; Gross CA; Lasser TA
    Radiology; 1995 Aug; 196(2):439-43. PubMed ID: 7617858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of gadobenate dimeglumine (MultiHance): Summary of findings from clinical studies and postmarketing surveillance.
    Shellock FG; Parker JR; Venetianer C; Pirovano G; Spinazzi A
    Invest Radiol; 2006 Jun; 41(6):500-9. PubMed ID: 16763468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Half-dose versus full-dose macrocyclic gadolinium at 3-T magnetic resonance imaging in paediatric bone and soft-tissue disease.
    Colafati GS; Rossi E; Carducci C; Piga S; Voicu IP; Mastronuzzi A; Tomà P
    Pediatr Radiol; 2018 Nov; 48(12):1724-1735. PubMed ID: 30046901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety assessment of gadobenate dimeglumine (MultiHance): extended clinical experience from phase I studies to post-marketing surveillance.
    Kirchin MA; Pirovano G; Venetianer C; Spinazzi A
    J Magn Reson Imaging; 2001 Sep; 14(3):281-94. PubMed ID: 11536405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inter- and intra-individual comparative study of two gadolinium-based agents: A pilot study.
    Shin KS; AlObaidy M; Ramalho M; Jeon YH; Burke LM; Altun E; Stallings CG; Semelka RC
    Abdom Imaging; 2015 Apr; 40(4):865-74. PubMed ID: 25223524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Structured Survey on Adverse Events Occurring Within 24 Hours After Intravenous Exposure to Gadodiamide or Gadoterate Meglumine: A Controlled Prospective Comparison Study.
    Parillo M; Sapienza M; Arpaia F; Magnani F; Mallio CA; DʼAlessio P; Quattrocchi CC
    Invest Radiol; 2019 Apr; 54(4):191-197. PubMed ID: 30379729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gadolinium-based contrast agents for imaging of the central nervous system: A multicenter European prospective study.
    Heshmatzadeh Behzadi A; McDonald J
    Medicine (Baltimore); 2022 Aug; 101(34):e30163. PubMed ID: 36042629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.